Articles
| Open Access |
https://doi.org/10.55640/
THE RELATIONSHIP BETWEEN LIVER FIBROSIS STAGES ASSESSED BY FIBROSCAN AND SERUM BIOMARKERS IN CHRONIC LIVER DISEASE
Kurbonov Khayitjon Shavkat ugli , Asia International University Bukhara,UzbekistanAbstract
Liver fibrosis is a critical factor in the progression of chronic liver diseases. FibroScan, a non-invasive transient elastography method, measures liver stiffness to assess fibrosis severity. Serum biomarkers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count, are used to calculate indices like APRI and FIB-4. This study evaluates the correlation between FibroScan liver stiffness measurements (LSM) and serum biomarkers in chronic liver disease patients.
Keywords
Liver Fibrosis, FibroScan, Transient Elastography, Serum Biomarkers, Non-invasive Diagnosis.
References
Friedman SL. Liver fibrosis — from bench to bedside. J Hepatol. 2003;38(Suppl 1):S38–S53.
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–218.
Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017–1044.
Bedossa P, Carrat F. Liver biopsy: The best, not the gold standard. J Hepatol. 2009;50(1):1–3.
Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–350.
Tapper EB, Lok AS. Use of liver stiffness measurement in clinical practice. Clin Gastroenterol Hepatol. 2017;15(9):1343–1354.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan in chronic liver disease. J Hepatol. 2019;70(3):562–569.
Hartl J, Denzer U, Ehlken H, et al. Transient elastography in autoimmune hepatitis. Hepatology. 2016;64(3):897–906.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325.
Cardoso AC, Carvalho-Filho RJ, Stern C, et al. FibroScan thresholds in viral hepatitis. Hepatology. 2017;66(3):595–602.
Kim WR, Berg T, Asselah T, et al. Noninvasive markers of fibrosis in NAFLD. Hepatology. 2016;64(4):1356–1369.
Article Statistics
Downloads
Copyright License
This work is licensed under a Creative Commons Attribution 4.0 International License.